Evaluation of the SARS-CoV-2-IgG response in outpatients by five commercial immunoassays

Abstract: Commercially available immunoassays have been developed for sensitive and specific detection of antibodies against SARS-CoV-2. While high sensitivity has been reported in hospitalized COVID-19 patients, little is known about the performance of the assays in ambulatory patients. Therefore, we evaluated the SARS-CoV-2-IgG response in 51 SASR-CoV-2-PCR-confirmed outpatients with five commercial immunoassays. The sensitivity in serum samples, collected at a median of 24 days after onset of symptoms, detected by the Anti-SARS-CoV-2-ELISA IgG (Euroimmun), EDI(TM) Novel Coronavirus COVID-19 IgG ELISA (Epitope Diagnostics), Liaison® SARS-CoV-2 S1/S2 IgG (Diasorin), SARS-CoV-2 IgG on the Architect(TM) i2000 (Abbott), and Elecsys® Anti-SARS-CoV-2 (IgM/IgA/IgG) on the cobas(TM) e801 (Roche) was 84.3%, 78.4%, 74.5%, 86.3%, and 88.2%, respectively. The sensitivity in serum samples, collected >20 days after onset of symptoms, varied between 75.0% and 90.0%, and in samples, collected at least 28...

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Evaluation of the SARS-CoV-2-IgG response in outpatients by five commercial immunoassays ; volume:8 ; day:16 ; month:09 ; year:2020 ; GMS infectious diseases ; 8 (16.09.2020)

Classification and Topics

• Classification: Medizin, Gesundheit

Contributors, Places and Time

• Creator: Wellinghausen, Nele ; Voss, Meike ; Ivanova, Ralitsa ; Deininger, Susanne

Further information

• DOI: 10.3205/id000066
• URN: urn:nbn:de:0183-id0000666
• Rights: Open Access; Open Access; Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 14.08.2025, 10:48 AM CEST